SEC Company Response from Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Dec 16, 2015
Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: Dec. 16, 2015 · CIK: 0001006281 · Accession: 0001144204-15-071293
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-208004
Letter
VIA EDGAR Office of Healthcare and Insurance Securities and Exchange Commission Division of Corporate Finance Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc., Registration Statement on Form S-3 Filed November 13, 2015 and amended on November 27, File No. 333-208004
Dear Ms. Hayes:
We refer to the registration statement on Form S-3 (File No. 333-208004) (as amended, the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Florida corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 4:05 p.m. (Eastern time) on December 18, 2015 or as soon as practicable thereafter.
The Company hereby acknowledges that:
· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or YossiM@protalix.com or the Company’s counsel, James R. Tanenbaum of Morrison & Foerster LLP at +1 (212) 468-8163 or jtanenbaum@mofo.com.
Sincerely,
/s/ Yossi Maimon
Show Raw Text
CORRESP 1 filename1.htm December 16, 2015 VIA EDGAR Suzanne Hayes Assistant Director Office of Healthcare and Insurance Securities and Exchange Commission Division of Corporate Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc., Registration Statement on Form S-3 Filed November 13, 2015 and amended on November 27, 2015 File No. 333-208004 Dear Ms. Hayes: We refer to the registration statement on Form S-3 (File No. 333-208004) (as amended, the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Florida corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 4:05 p.m. (Eastern time) on December 18, 2015 or as soon as practicable thereafter. The Company hereby acknowledges that: · should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or YossiM@protalix.com or the Company’s counsel, James R. Tanenbaum of Morrison & Foerster LLP at +1 (212) 468-8163 or jtanenbaum@mofo.com. Sincerely, /s/ Yossi Maimon Yossi Maimon Vice President and Chief Financial Officer Protalix BioTherapeutics, Inc. cc: Moshe Manor Protalix BioTherapeutics, Inc. James R. Tanenbaum Morrison & Foerster LLP 2 Snunit Street, Science Park P.O.B. 455, Carmiel 20100, Israel Tel: 972-4-988-9488 | Fax: 972-4-988-9489 | Web: www.protalix.com